Response to Ergonul: Scientific Evidence Versus Personal Beliefs In Crimean-Congo Haemorrhagic Fever Treatment

Journal of Infection

Volumn 59, Issue 4, 2009, Pages 286-289

  Ascioglu, Sibel ^a   Leblebicioglu, Hakan ^b   Elaldi, Nazif ^c   Bodur, Hurrem ^d   Vahaboglu, Haluk ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c CUMHURIYET UNIVERSITY   (Turkey)

^d ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e KOCAELI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ADVERSE OUTCOME; BIOSTATISTICS; CLINICAL TRIAL; CONFOUNDING VARIABLE; DISEASE SEVERITY; DRUG CHOICE; EFFECT SIZE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INCUBATION TIME; INFLUENZA; LABORATORY TEST; LASSA FEVER; LETTER; MEDICAL ETHICS; QUASI EXPERIMENTAL STUDY; SAMPLE SIZE; SAMPLING ERROR; SCIENTIFIC LITERATURE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION;

EID: 72049132632     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.08.017     Document Type: Letter

References (20)

1. Rothman K.J., and Greenland S. Modern epidemiology. 2nd ed. (1998), Lippincott-Raven, Philadelphia p. 183-199
2. Friedman L.M., and Furberg C.D. DeMetsDL. Fundamentals of clinical trials. 3rd ed. (1998), Springer-Verlag, New York p. 94-125
3. Glanz S.A. What does "not significant" really mean? Primer of biostatistics. 4th ed. (1997), McGraw-Hill, USA p. 151-183
4. Goodman S.N., and Berlin J.A. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting the results. Ann Intern Med 121 (1994) 200-206
5. Hennekens C., and Buring J.E. Observational evidence. Ann NY Acad Sci 703 (1993) 18-24
6. Horwitz R.I., and Feinstein A.R. The problem of "protopathic bias" in case-control studies. Am J Med 68 2 (1980) 255-258
7. Salas M., Hofman A., and Stricker B.H.C. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 149 11 (1999) 981-983
8. Chapman L.E. How medicine advances. Clin Infect Dis 48 (2009) 407-409
9. Chiou H.E., Liu C.L., Buttrey M.J., Kuo H.P., Liu H.W., Kuo H.T., et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centres. Chest 128 (2005) 263-272
10. Shadish W.R., Cook T.D., and Campell D.T. Experimental and quasi-experimental designs for generalized casual inferences (2002), Houghton Mifflin Company, Boston
11. Harris A.D., Bradham D.D., Baumgarten M., Zuckerman I.H., Fink J.C., and Perencevich E.N. The use and interpretation of quasi experimental studies in infection disease. Clin Infect Dis 38 (2004) 586-591
12. Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334 7586 (2007) 197
13. Mardani M., Jahromi M.K., Naieni K.H., and Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 36 (2003) 1613-1618
14. Ergonul O., Celikbas A., Dokuzoguz B., Eren S., Baykam N., and Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 39 (2004) 284-287
15. Alavi-Naini R., Moghtaderi A., Koohpayeh H.R., Koohpayeh H.R., Sharifi-Mood B., Naderi M., et al. Crimean-Congo hemorrhagic fever in Southeast of Iran. J Infect 52 (2006) 378-382
16. Ozkurt Z., Kiki I., Erol S., Erdem F., Yilmaz N., Parlak M., et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 52 (2006) 207-215
17. Cevik M.A., Elaldi N., Akinci E., Ongürü P., Erbay A., Buzgan T., et al. A preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean-Congo hemorrhagic fever. J Infect 57 (2008) 350-351
18. Tasdelen F.N., Ergonul O., Doganci L., and Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 28 (2009) 929-933
19. Elaldi N., Bodur H., Ascioglu S., Celikbas A., Ozkurt Z., Vahaboglu H., et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect 58 (2009) 238-244
20. Yilmaz R.G., Buzgan T., Irmak H., Safran A., Uzun R., Cevik M.A., et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis 13 (2009) 380-386